Antibodies of PARK7


2 antibodies are included.     

 Released    NotSatisfied    Submitted    NotReviewed    OnHold    Submitting    Experimented   
RBP Antibody InfoPrimary-HepG2Secondary-HepG2Primary-K562Secondary-K562Primary-UBERONPrimary-Hela
PARK7Product_ID: 5560S
Lot_ID: 1
Source: Cell Signaling Technology
Target Name: PARK7-human		 PARK7-HEPG2-CRISPR-5560S.png<br>Caption: Western blot following CRISPR against PARK7 in HepG2 whole cell lysate using PARK7 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different CRISPR against PARK7. PARK7 protein appears as the green arrow, Beta-actin serves as a control and appears in red arrow.
 CST_5560S_1_PARK7.png<br>Caption: IP-WB analysis of 5560S whole cell lysate using the PARK7 specific antibody, 5560S. Lanes 1 and 2 are 2.5% of five million whole cell lysate input and 50% of IP enrichment, respectively, using a normal IgG antibody. Lane 3 is 50% of IP enrichment from five million whole cell lysate using the PARK7-specific antibody, 5560S. The same antibody was used to detect protein levels via Western blot. This antibody passes preliminary validation and will be further pursued for secondary validation. *NOTE* Protein sizes are taken from Genecards.org and are only estimates based on sequence. Actual protein size may differ based on protein characteristics and electrophoresis method used.
 PARK7-K562-CRISPR-5560S.png<br>Caption: Western blot following CRISPR against PARK7 in K562 whole cell lysate using PARK7 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different CRISPR against PARK7. PARK7 protein appears as the green arrow, Beta-actin serves as a control and appears in red arrow.
PARK7Product_ID: 5933S
Lot_ID: 1
Source: Cell Signaling
Target Name: PARK7-human		 CST_5933S_2_PARK7.png<br>Caption: IP-WB analysis of 5933S whole cell lysate using the PARK7 specific antibody, 5933S. Lanes 1 and 2 are 2.5% of five million whole cell lysate input and 50% of IP enrichment, respectively, using a normal IgG antibody. Lane 3 is 50% of IP enrichment from five million whole cell lysate using the PARK7-specific antibody, 5933S. The same antibody was used to detect protein levels via Western blot. This antibody passes preliminary validation and will be further pursued for secondary validation. *NOTE* Protein sizes are taken from Genecards.org and are only estimates based on sequence. Actual protein size may differ based on protein characteristics and electrophoresis method used.
 PARK7-K562-CRISPR-5933S.png<br>Caption: Western blot following CRISPR against PARK7 in K562 whole cell lysate using PARK7 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different CRISPR against PARK7. PARK7 protein appears as the green arrow, Beta-actin serves as a control and appears in red arrow.